{"result": "(\"entity\"<|>COLITIS ULCEROSA<|>EVENT<|>Colitis ulcerosa is an autoimmune disease characterized by inflammation of the colon, leading to symptoms such as rectal bleeding and abdominal pain.)\n##\n(\"entity\"<|>ENFERMEDAD DE CROHN<|>EVENT<|>Enfermedad de Crohn is an inflammatory bowel disease that can affect any part of the gastrointestinal tract, causing symptoms like abdominal pain and diarrhea.)\n##\n(\"entity\"<|>ENFERMEDAD INFLAMATORIA INTESTINAL<|>EVENT<|>Enfermedad inflamatoria intestinal encompasses conditions like colitis ulcerosa and enfermedad de Crohn, which cause chronic inflammation of the gastrointestinal tract.)\n##\n(\"entity\"<|>OSTEOPOROSIS<|>EVENT<|>Osteoporosis is a condition characterized by weakened bones, which can be a manifestation of extraintestinal complications related to inflammatory bowel diseases.)\n##\n(\"entity\"<|>ANEMIA<|>EVENT<|>Anemia is a condition that can occur as a secondary effect of chronic inflammation and malabsorption in patients with inflammatory bowel diseases.)\n##\n(\"entity\"<|>SULFASALACINA<|>EVENT<|>Sulfasalacina is a medication used as a first-line treatment for colitis ulcerosa, helping to reduce inflammation in the colon.)\n##\n(\"relationship\"<|>COLITIS ULCEROSA<|>ENFERMEDAD INFLAMATORIA INTESTINAL<|>Colitis ulcerosa is a specific type of inflammatory bowel disease, thus it is a subset of the broader category of enfermedad inflamatoria intestinal.<|>8)\n##\n(\"relationship\"<|>ENFERMEDAD DE CROHN<|>ENFERMEDAD INFLAMATORIA INTESTINAL<|>Enfermedad de Crohn is another specific type of inflammatory bowel disease, making it part of the broader category of enfermedad inflamatoria intestinal.<|>8)\n##\n(\"relationship\"<|>COLITIS ULCEROSA<|>SULFASALACINA<|>Sulfasalacina is used as a treatment for colitis ulcerosa, indicating a direct relationship between the medication and the disease.<|>9)\n##\n(\"relationship\"<|>ENFERMEDAD DE CROHN<|>ANEMIA<|>Anemia can be a complication of enfermedad de Crohn due to chronic inflammation and malabsorption, linking the disease to this condition.<|>7)\n##\n(\"relationship\"<|>ENFERMEDAD INFLAMATORIA INTESTINAL<|>OSTEOPOROSIS<|>Osteoporosis can be a complication associated with inflammatory bowel diseases, indicating a relationship between the two.<|>6)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: de una enfermedad de origen autoinmune, puede presentar manifestaciones a nivel de otros órganos.\n\n#### 2.2.1. Colitis ulcerosa\n\nLas manifestaciones dependen de la extensión, localización y magnitud de las lesiones. Los síntomas cardinales son: rectorragia y presencia de moco-pus en heces por la fragilidad de la mucosa, acompañado de dolor abdominal cólico y diarrea con síndrome rectal (tenesmo, urgencia deposicional). Cuando aumenta la severidad de la inflamación es más probable la aparición de síntomas sistémicos (fiebre, anorexia, pérdida de peso, náuseas y vómitos), como complicaciones: megacolon tóxico y aumento de riesgo de adenocarcinoma colorrectal, entre otras9.\n\n#### 2.2.2. Enfermedad de Crohn\n\nSu localización variable y la afectación transmural condicionan la aparición de estenosis y trayectos fistulosos. Los datos clínicos más frecuentes son dolor ab-\n---\nTema 30. Soporte nutricional en la enfermedad inflamatoria intestinal 483\n\ndominal (de características diferentes según la localiza-\nción, que precede a la diarrea y se alivia con la\ndefecación) y diarrea multifactorial, asociado con pér-\ndida de peso por diarrea o por malabsorción; es mas\nfrecuente en la EC que en la CU, la presencia de masas\no plastrones inflamatorios propios de esta entidad9. En\nla EC comparada con la CU, el dolor abdominal y la\npérdida de peso son más frecuentes y persistentes13.\n\n### 2.2.3. Manifestaciones extraintestinales\n\n1) Osteoarticulares: osteoporosis y osteomalacia, ar-\n   tritis periférica asimétrica (15-20%), espondilitis\n   anquilosante (10%) y sacroileítis.\n2) Cutáneo-mucosas: eritema nodoso, pioderma\n   gangrenoso y estomatitis aftosa.\n3) Hepáticas: colangitis esclerosante primaria, co-\n   langiocarcinoma, esteatosis por desnutrición, he-\n   patitis autoinmune y colelitiasis.\n4) Oculares: uveítis, escleritis y episcleritis.\n5) Renales: nefrolitiasis, insuficiencia renal por ami-\n   loidosis secundaria y uropatía obstructiva.\n6) Hematológicas: anemia secundaria a pérdidas\n   crónicas, malabsorción y déficit de micronutrien-\n   tes. Trombosis venosa profunda.\n\n### 2.3. Aproximación diagnóstica de la enfermedad inflamatoria intestinal\n\n#### 2.3.1. Sospecha clínica\n\nDebe ponernos en alerta una historia clínica compatible.\nAunque en muchas ocasiones, como en niños, la clínica es\nlarvada, manifestándose únicamente como retraso en el\ncrecimiento hasta en un 46%14 de los casos. Junto con\nsignos endoscópicos propios de la enfermedad y datos\nhistológicos compatibles se establece el diagnóstico, así\ncomo el posible uso novedoso de cápsula endoscópica15.\n\n#### 2.3.2. Exclusión de otras enfermedades\n\nPrincipalmente de infecciones intestinales con gran\ncomponente inflamatorio e invasión de la pared intes-\ntinal por microorganismos como Salmonella, Shigella,\nYersinia, Campylobacter, Aeromonas, C. difficile, E.\ncoli 0157: H7, Entamoeba histolytica y bacilo de Koch.\n\n#### 2.3.3. Diferenciación entre enfermedad de Crohn y colitis ulcerosa\n\nEn ocasiones, cuando la EC afecta únicamente al co-\nlon puede ser difícil diferenciarla de la CU, denominán-\ndose colitis indeterminada. En la actualidad aún no\nexiste un patrón oro para el diagnóstico.\n\n#### 2.3.4. Grado de actividad\n\nMediante la medición plasmática de reactantes de\nfase aguda: velocidad de sedimentación globular (VSG),\n\nproteína C reactiva (PCR), beta 2 microglobulina). Exis-\nten otros índices de actividad tipo endoscópico, histoló-\ngico y de calidad de vida.\n\n### 2.4. Tratamiento médico\n\n#### 2.4.1. Sulfasalacina y aminosalicilatos (mesalamina, sulfasalazina, olsalazina y balsalacida)\n\nConstituyen la primera línea de tratamiento en la CU,\ntanto en la inducción como en el mantenimiento de la\nremisión16. Se pueden aplicar en forma de enemas o\nsupositorios para formas distales. Poseen acción antiin-\nflamatoria disminuyendo los radicales libres\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}